{"doi":"10.3390/vaccines10101672","title":"Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose","abstract":"<jats:p>This study aimed to determine the anti-S (receptor binding protein) RBD IgG antibody titers formed against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and the neutralizing antibody inhibition percentages (nAb IH%) in blood samples taken after two doses of inactive or mRNA-based vaccine and a booster dose. Volunteers with two doses of inactivated CoronaVac (heterologous group; n = 75) and BioNTech (BNT)162b2 mRNA vaccine (homologous group; n = 75) were included in this study. All participants preferred the BNT162b2 vaccine as a booster dose. First, peripheral blood samples were taken 3 months after the second vaccine dose. Second, peripheral blood samples were taken 1 month after the booster dose. Anti-S-RBD IgG titers were determined by CMIA (SARS-CoV-2 IgG II Quant). Neutralizing antibodies were detected by a surrogate neutralization assay (SARS-CoV-2 NeutraLISA, Euroimmun, Lübeck, Germany). The median age of the volunteers was 40 (IQR 29–47) years old. After the heterologous booster dose, anti-S-RBD IgG levels and neutralizing antibodies increased approximately 50-fold and 9-fold, respectively. Anti-S-RBD IgG titers increased by 9 and 57 times, respectively, while nAb IH% increased by 1.5 and 16 times, respectively, among those with heterologous reminder doses and those with and without a prior history of coronavirus disease (COVID-19). This study showed that after the administration of a heterologous booster dose with BNT162b2 to those whose primary vaccination was with inactivated CoronaVac, the binding and neutralizing antibody levels were similar to those who received a homologous BNT162b2 booster dose. It was observed that the administration of heterologous and homologous booster doses resulted in the development of similar levels of neutralizing antibodies, independently from a prior history of COVID-19.</jats:p>","journal":"Vaccines","year":2022,"id":637814,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1656296,"name":"Mehmet Demirci","orcid":"0000-0001-9670-2426","position":1,"is_corresponding":false},{"id":1656297,"name":"Dogukan Ozbey","orcid":null,"position":2,"is_corresponding":false},{"id":1656299,"name":"Ferhat Dasdemir","orcid":"0000-0003-3836-1680","position":3,"is_corresponding":false},{"id":1656300,"name":"Harika Oyku Dinc","orcid":"0000-0003-3628-7392","position":4,"is_corresponding":false},{"id":1656301,"name":"Ilker Inanc Balkan","orcid":null,"position":5,"is_corresponding":false},{"id":1656302,"name":"Suat Saribas","orcid":"0000-0002-4549-3887","position":6,"is_corresponding":false},{"id":1656303,"name":"Neşe Saltoglu","orcid":null,"position":7,"is_corresponding":false},{"id":675462,"name":"Bekir Kocazeybek","orcid":"0000-0003-1072-3846","position":8,"is_corresponding":false},{"id":1656295,"name":"Nesrin Gareayaghi","orcid":"0000-0002-0812-1128","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose","abstract":"<jats:p>This study aimed to determine the anti-S (receptor binding protein) RBD IgG antibody titers formed against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and the neutralizing antibody inhibition percentages (nAb IH%) in blood samples taken after two doses of inactive or mRNA-based vaccine and a booster dose. Volunteers with two doses of inactivated CoronaVac (heterologous group; n = 75) and BioNTech (BNT)162b2 mRNA vaccine (homologous group; n = 75) were included in this study. All participants preferred the BNT162b2 vaccine as a booster dose. First, peripheral blood samples were taken 3 months after the second vaccine dose. Second, peripheral blood samples were taken 1 month after the booster dose. Anti-S-RBD IgG titers were determined by CMIA (SARS-CoV-2 IgG II Quant). Neutralizing antibodies were detected by a surrogate neutralization assay (SARS-CoV-2 NeutraLISA, Euroimmun, Lübeck, Germany). The median age of the volunteers was 40 (IQR 29–47) years old. After the heterologous booster dose, anti-S-RBD IgG levels and neutralizing antibodies increased approximately 50-fold and 9-fold, respectively. Anti-S-RBD IgG titers increased by 9 and 57 times, respectively, while nAb IH% increased by 1.5 and 16 times, respectively, among those with heterologous reminder doses and those with and without a prior history of coronavirus disease (COVID-19). This study showed that after the administration of a heterologous booster dose with BNT162b2 to those whose primary vaccination was with inactivated CoronaVac, the binding and neutralizing antibody levels were similar to those who received a homologous BNT162b2 booster dose. It was observed that the administration of heterologous and homologous booster doses resulted in the development of similar levels of neutralizing antibodies, independently from a prior history of COVID-19.</jats:p>","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36298537","pmcid":"PMC9609633","openalex_id":"https://openalex.org/W4304190077","authors":[],"funders":[{"funder_name":"IU-Cerrahpaşa Scientific Research Projects Unit","grant_id":"36854","title":null}],"total_grants":1,"fwci":0.2898,"citation_percentile":0.54758359,"influential_citations":0,"citation_trend":[{"year":2023,"count":2},{"year":2025,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2076-393X/10/10/1672/pdf?version=1666690628","host_type":"journal"},{"url":"https://www.mdpi.com/2076-393X/10/10/1672/pdf?version=1666690628","host_type":"publisher"},{"url":"https://www.mdpi.com/2076-393X/10/10/1672/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/vaccines10101672","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36298537","host_type":"repository"},{"url":"https://doaj.org/article/9e2045e70508420f8c6872f768242374","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9609633","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9609633","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9609633?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["SARS-CoV-2 and COVID-19 Research","COVID-19 Clinical Research Studies","Animal Virus Infections Studies"],"mesh_terms":[],"keywords":["Heterologous","Booster dose","Neutralizing antibody","Antibody","Medicine","Titer","Booster (rocketry)","Virology","Neutralization","Immunology","Vaccination","Antibody titer","Chemistry","Binding Antibody","Bnt162b2","Coronavac"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T19:34:43.532281Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}